In 2020, Zhang et al. described a tripeptide lipid nanoparticle loaded with paclitaxel and anti-VEGF siRNA that successfully delivered the medicinal cargo to lung cancer cells, leading to an important anti-tumor effect, by inhibiting VEGF expression and inducing apoptosis [105], underscoring the significant role of liposomes in lung cancer management, particularly in therapies targeting the downregulation of VEGF. Here, VEGFA is linked to lung carcinoma.